In the United States alone, approximately 25,000 newborns are born extremely premature (EPT) with high mortality due to their severely undeveloped lungs.
Although current NICU technology enables survival, there’s a definitive need for life support that mitigates resulting severe chronic complications associated with this vulnerable population.
SiMOx-AP is a novel artificial placenta oxygenator that provides respiratory support that mimics placental gas exchange to overcome key clinical obstacles in EPT care.
MTM Student Engagement
In collaboration with UCSF’s Roy Lab, our team has significantly contributed to engineering a second-generation device and performing analyses on business strategy, regulatory approach, and intellectual property. This ultimately will help change the paradigm of neonatal care and improve EPT patient outcomes.